ContraFect to Present New Data on CF-301 at ID Week 2017
September 29 2017 - 7:00AM
ContraFect Corporation (NASDAQ:CFRX), a
biotechnology company focused on the discovery and development of
protein and antibody therapeutics for life-threatening,
drug-resistant infectious diseases, today announces poster
presentations of new data from the CF-301 development program at
the ID Week 2017 conference to be held on October 4-8, 2017 in San
Diego, CA.
“We are pleased to present new data which further support the
intended use of CF-301 for the treatment of Staphylococcus aureus
(Staph aureus) infections. These new data extend previous
reports of CF-301’s synergy with conventional antibiotics to a
wider range of commonly used anti-staphylococcal antibiotics and
suggest that CF-301 may enhance the ability of antibiotics to treat
serious infections. We are further encouraged by the additional
surveillance data which show the potent activity of CF-301 against
current Staph aureus strains from infected patients in diverse
geographies,” said Cara Cassino, M.D., EVP of Research and
Development and Chief Medical Officer at ContraFect.
Presentation Details:
Session Title: Expanded Spectrum - New
Antimicrobial Susceptibility Testing
Presentation Title: Lysin CF-301 Demonstrates
In Vitro Synergy with Conventional Antibiotics against
Staphylococcus aureusSession Day & Time:
Friday, October 6, 2017 12:30 PM – 2:00 PM PT (3:30 PM – 5:00 PM
ET) Poster Number: 1212
Presentation Title: Activity of
Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus
aureus Clinical Isolates from the USA and Europe Session
Day & Time: Friday, October 6, 2017 12:30 PM – 2:00 PM
PT (3:30 PM – 5:00 PM ET) Poster number: 1213
The abstracts can be accessed through the ID Week website.
Following the meeting, the presentation posters will be available
on the ContraFect Corporation website.
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza. ContraFect is also conducting research
focused on the discovery of lysins to target Gram-negative
bacteria.
About CF-301:
CF-301 is a recombinant bacteriophage-derived lysin with potent
bactericidal activity against Staph aureus, a major cause of blood
stream infections, or bacteremia. CF-301 has the potential to be a
first-in-class treatment for Staph aureus bacteremia. It has
a novel, rapid, and specific mechanism of bactericidal action
against Staph aureus and does not impact the body's natural
bacterial flora. By targeting a conserved region of the cell wall
that is vital to bacteria, resistance is less likely to develop to
CF-301. Combinations of CF-301 with standard of care antibiotics
significantly increased bacterial killing and survival in animal
models of disease when compared to treatment with antibiotics or
CF-301 alone. In addition, in vitro and in vivo experiments have
shown that CF-301 is highly active against biofilm infections.
CF-301 was licensed from The Rockefeller University and is being
developed at ContraFect. CF-301 is currently being studied in a
Phase 2 multicenter, multinational, randomized, controlled clinical
trial in patients with Staph aureus bacteremia including
endocarditis.
Forward-Looking Statements
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, whether new
data on CF-301 supports its intended use, our ability to address
life threatening infections using our therapeutic product
candidates from our lysin and monoclonal antibody platforms to
target conserved regions of either bacteria or viruses, whether our
initial product candidates can treat antibiotic-resistant
infections such as MRSA (Methicillin-resistant Staph aureus) and
influenza, our ability to discover new lysins targeting
Gram-negative bacteria and the potential for CF-301 to be a
first-in-class treatment for Staph aureus bacteremia.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contact
Paul Boni
ContraFect Corporation
Tel: 914-207-2300
Email: pboni@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024